These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26598495)

  • 1. Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.
    Kimbrough IF; Robel S; Roberson ED; Sontheimer H
    Brain; 2015 Dec; 138(Pt 12):3716-33. PubMed ID: 26598495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease.
    Wilcock DM; Vitek MP; Colton CA
    Neuroscience; 2009 Mar; 159(3):1055-69. PubMed ID: 19356689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrovascular pathology during the progression of experimental Alzheimer's disease.
    Giannoni P; Arango-Lievano M; Neves ID; Rousset MC; Baranger K; Rivera S; Jeanneteau F; Claeysen S; Marchi N
    Neurobiol Dis; 2016 Apr; 88():107-17. PubMed ID: 26774030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice.
    Merlini M; Meyer EP; Ulmann-Schuler A; Nitsch RM
    Acta Neuropathol; 2011 Sep; 122(3):293-311. PubMed ID: 21688176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of perivascular cells and myocytes in vascular amyloidosis.
    Wisniewski HM; Wegiel J; Vorbrodt AW; Mazur-Kolecka B; Frackowiak J
    Ann N Y Acad Sci; 2000 Apr; 903():6-18. PubMed ID: 10818483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease.
    Lee AJ; Raghavan NS; Bhattarai P; Siddiqui T; Sariya S; Reyes-Dumeyer D; Flowers XE; Cardoso SAL; De Jager PL; Bennett DA; Schneider JA; Menon V; Wang Y; Lantigua RA; Medrano M; Rivera D; Jiménez-Velázquez IZ; Kukull WA; Brickman AM; Manly JJ; Tosto G; Kizil C; Vardarajan BN; Mayeux R
    Acta Neuropathol; 2022 Jul; 144(1):59-79. PubMed ID: 35608697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
    Kuznetsova E; Schliebs R
    Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex interplay between brain function and structure during cerebral amyloidosis in APP transgenic mouse strains revealed by multi-parametric MRI comparison.
    Grandjean J; Derungs R; Kulic L; Welt T; Henkelman M; Nitsch RM; Rudin M
    Neuroimage; 2016 Jul; 134():1-11. PubMed ID: 27033685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronally Derived Soluble Abeta Evokes Cell-Wide Astrocytic Calcium Dysregulation in Absence of Amyloid Plaques
    Kelly P; Sanchez-Mico MV; Hou SS; Whiteman S; Russ A; Hudry E; Arbel-Ornath M; Greenberg SM; Bacskai BJ
    J Neurosci; 2023 Jun; 43(26):4926-4940. PubMed ID: 37236808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.
    Mori T; Koyama N; Arendash GW; Horikoshi-Sakuraba Y; Tan J; Town T
    Glia; 2010 Feb; 58(3):300-14. PubMed ID: 19705461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.
    Magga J; Puli L; Pihlaja R; Kanninen K; Neulamaa S; Malm T; Härtig W; Grosche J; Goldsteins G; Tanila H; Koistinaho J; Koistinaho M
    J Neuroinflammation; 2010 Dec; 7():90. PubMed ID: 21138577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model.
    Thanopoulou K; Fragkouli A; Stylianopoulou F; Georgopoulos S
    Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20816-21. PubMed ID: 21076037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.
    Matsuoka Y; Picciano M; Malester B; LaFrancois J; Zehr C; Daeschner JM; Olschowka JA; Fonseca MI; O'Banion MK; Tenner AJ; Lemere CA; Duff K
    Am J Pathol; 2001 Apr; 158(4):1345-54. PubMed ID: 11290552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of voluntary running on cerebrovascular morphology and spatial short-term memory in a mouse model of amyloidosis.
    Maliszewska-Cyna E; Vecchio LM; Thomason LAM; Oore JJ; Steinman J; Joo IL; Dorr A; McLaurin J; Sled JG; Stefanovic B; Aubert I
    Neuroimage; 2020 Nov; 222():117269. PubMed ID: 32818618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis.
    Ferretti MT; Merlini M; Späni C; Gericke C; Schweizer N; Enzmann G; Engelhardt B; Kulic L; Suter T; Nitsch RM
    Brain Behav Immun; 2016 May; 54():211-225. PubMed ID: 26872418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology.
    Lüth HJ; Holzer M; Gärtner U; Staufenbiel M; Arendt T
    Brain Res; 2001 Sep; 913(1):57-67. PubMed ID: 11532247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model.
    Qiao J; Wang J; Wang H; Zhang Y; Zhu S; Adilijiang A; Guo H; Zhang R; Guo W; Luo G; Qiu Y; Xu H; Kong J; Huang Q; Li XM
    Glia; 2016 Feb; 64(2):240-54. PubMed ID: 26446044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocytic gap junctional communication is reduced in amyloid-β-treated cultured astrocytes, but not in Alzheimer's disease transgenic mice.
    Cruz NF; Ball KK; Dienel GA
    ASN Neuro; 2010 Aug; 2(4):e00041. PubMed ID: 20730033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
    Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E
    J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.
    Zhou J; Fonseca MI; Pisalyaput K; Tenner AJ
    J Neurochem; 2008 Sep; 106(5):2080-92. PubMed ID: 18624920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.